Related Experiment Video

Updated: Aug 15, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives

Myrna Candelaria1, Lucia Taja-Chayeb, Claudia Arce-Salinas

  • 1Division of Clinical Research, Instituto Nacional de Cancerología, UNAM, Tlalpan, Mexico. myrnac@prodigy.net.mx

Anti-Cancer Drugs
|September 16, 2005
PubMed

Insights

Genetic variations in drug-metabolizing enzymes impact treatment outcomes. Pre-screening patients for specific polymorphisms can personalize chemotherapy, improving drug efficacy and reducing severe toxicity risks.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Molecular Biology

Background:

  • Drug-metabolizing enzymes (DMEs) are crucial for activating or detoxifying cytotoxic drugs.
  • Allelic variants of DMEs occur with varying frequencies globally, influencing drug efficacy and toxicity.
  • Polymorphisms in DMEs like TPMT, DPD, UGT1A1, and TYMS are linked to altered drug metabolism and severe adverse events.

Purpose of the Study:

  • To review the impact of genetic polymorphisms in key drug-metabolizing enzymes on the therapeutic index of cytotoxic drugs.
  • To highlight the clinical utility of pharmacogenetic screening for optimizing cancer chemotherapy.

Main Methods:

  • Review of existing literature on drug-metabolizing enzyme polymorphisms and their clinical implications.
  • Analysis of specific examples including TPMT, DPD, UGT1A1, and TYMS polymorphisms.
  • Discussion of genotype-guided drug selection and dosing strategies.

Main Results:

  • Thiopurine methyltransferase (TPMT) and dihydropyrimidine dehydrogenase (DPD) polymorphisms correlate with altered metabolism and toxicity of 6-mercaptopurine and 5-fluorouracil.
  • UGT1A1 promoter variants affect SN-38 glucuronidation, leading to irinotecan toxicity (diarrhea, neutropenia).
  • Thymidylate synthase (TYMS) polymorphisms are associated with both pyrimidine-related toxicity and chemotherapy response.

Conclusions:

  • Pharmacogenetic testing for well-characterized polymorphisms is valuable for identifying optimal and safe chemotherapy regimens.
  • Pre-screening patients can personalize treatment, enhancing therapeutic outcomes and minimizing severe drug toxicities.
  • Genomic approaches offer a promising strategy for tailoring cancer therapy to individual patient profiles.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...